ACC-NK (Antibody-cell Conjugate NK) integrates the antigen-targeting function of antibodies and the immune killing function of NK cells through antibody conjugation technology (non-viral vector, non-gene editing). By targeting specific tumor antigens with antibodies, it can quickly and efficiently guide NK cells to recognize and kill tumor cells.
Preventing tumor recurrence after surgery
Solid tumor treatment
Warburg combined with NK treatment for advanced solid tumors
Proton and heavy ion therapy combined with NK cell therapy for solid tumors
Embryonic trophoblast glycoprotein (5T4) is an N-glycosylated transmembrane protein involved in the immune exemption process of embryonic cells. 5T4 is highly expressed in embryonic trophoblast cells, covering more than 90% of solid tumors. 5T4 has been expressed in precancerous lesions (such as colon polyps and lung nodules), and ACC-NK (IBR854) can be cleared early to block the carcinogenesis process.
InbioMed's ACC-NK cell therapy targeting Trop-2 is the world's first of its kind, boasting immense therapeutic potential through IO+ADC. It circumvents the issues and potential risks associated with Trop-2-targeted ADC products, such as high toxicity and a narrow therapeutic window. ACC-NK8 (IBR822) introduces a novel treatment paradigm. When combined with ADC, radiotherapy, and chemotherapy, it can reduce side effects, significantly enhance efficacy, and prolong patient survival.
The CD33-CLL1 dual-target FIC therapy simultaneously targets and kills AML cells and leukemia stem cells, demonstrating remarkable efficacy in inhibiting and improving advanced hematological tumors.
Scan the QR code to learn more
Consultation Hotline400-995-9976
Copyright2025 英百瑞（杭州）医学研究有限公司 All Rights Reserved. 浙ICP备2025205905号 DESIGN BY : WEETOP
